Literature DB >> 24186360

Counteracting neuronal nitric oxide synthase proteasomal degradation improves glucose transport in insulin-resistant skeletal muscle from Zucker fa/fa rats.

Karima Mezghenna1, Jérémy Leroy, Jacqueline Azay-Milhau, Didier Tousch, Françoise Castex, Sylvain Gervais, Viviana Delgado-Betancourt, René Gross, Anne-Dominique Lajoix.   

Abstract

AIMS/HYPOTHESIS: Insulin-mediated glucose transport and utilisation are decreased in skeletal muscle from type 2 diabetic and glucose-intolerant individuals because of alterations in insulin receptor signalling, GLUT4 translocation to the plasma membrane and microvascular blood flow. Catalytic activity of the muscle-specific isoform of neuronal nitric oxide synthase (nNOS) also participates in the regulation of glucose transport and appears to be decreased in a relevant animal model of drastic insulin resistance, the obese Zucker fa/fa rat. Our objective was to determine the molecular mechanisms involved in this defect.
METHODS: Isolated rat muscles and primary cultures of myocytes were used for western blot analysis of protein expression, immunohistochemistry, glucose uptake measurements and GLUT4 translocation assays.
RESULTS: nNOS expression was reduced in skeletal muscle from fa/fa rats. This was caused by increased ubiquitination of the enzyme and subsequent degradation by the ubiquitin proteasome pathway. The degradation occurred through a greater interaction of nNOS with the chaperone heat-shock protein 70 and the co-chaperone, carboxyl terminus of Hsc70-interacting protein (CHIP). In addition, an alteration in nNOS sarcolemmal localisation was observed. We confirmed the implication of nNOS breakdown in defective insulin-induced glucose transport by demonstrating that blockade of proteasomal degradation or overexpression of nNOS improved basal and/or insulin-stimulated glucose uptake and GLUT4 translocation in primary cultures of insulin-resistant myocytes. CONCLUSIONS/
INTERPRETATION: Recovery of nNOS in insulin-resistant muscles should be considered a potential new approach to address insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24186360     DOI: 10.1007/s00125-013-3084-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  52 in total

1.  Primary rat muscle progenitor cells have decreased proliferation and myotube formation during passages.

Authors:  S Machida; E E Spangenburg; F W Booth
Journal:  Cell Prolif       Date:  2004-08       Impact factor: 6.831

2.  Expression of the skeletal muscle dystrophin-dystroglycan complex and syntrophin-nitric oxide synthase complex is severely affected in the type 2 diabetic Goto-Kakizaki rat.

Authors:  Claire Mulvey; Erika Harno; Alan Keenan; Kay Ohlendieck
Journal:  Eur J Cell Biol       Date:  2005-11       Impact factor: 4.492

Review 3.  Skeletal muscle satellite cell cultures.

Authors:  R E Allen; C J Temm-Grove; S M Sheehan; G Rice
Journal:  Methods Cell Biol       Date:  1997       Impact factor: 1.441

4.  Inhibition of hsp70 by methylene blue affects signaling protein function and ubiquitination and modulates polyglutamine protein degradation.

Authors:  Adrienne M Wang; Yoshihiro Morishima; Kelly M Clapp; Hwei-Ming Peng; William B Pratt; Jason E Gestwicki; Yoichi Osawa; Andrew P Lieberman
Journal:  J Biol Chem       Date:  2010-03-26       Impact factor: 5.157

5.  Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients.

Authors:  A Avogaro; F Piarulli; A Valerio; M Miola; M Calveri; P Pavan; P Vicini; C Cobelli; A Tiengo; L Calò; S Del Prato
Journal:  Diabetes       Date:  1997-06       Impact factor: 9.461

6.  Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle.

Authors:  M E Young; B Leighton
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

7.  Nitric oxide stimulates skeletal muscle glucose transport through a calcium/contraction- and phosphatidylinositol-3-kinase-independent pathway.

Authors:  G J Etgen; D A Fryburg; E M Gibbs
Journal:  Diabetes       Date:  1997-11       Impact factor: 9.461

8.  Protein inhibitor of neuronal nitric oxide synthase (PIN) is a new regulator of glucose-induced insulin secretion.

Authors:  Anne-Dominique Lajoix; Stéphanie Badiou; Sylvie Péraldi-Roux; Thierry Chardès; Samuel Dietz; Cindy Aknin; Florence Tribillac; Pierre Petit; René Gross
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

9.  Fuel oxidation in skeletal muscle is increased by nitric oxide/cGMP--evidence for involvement of cGMP-dependent protein kinase.

Authors:  M E Young; B Leighton
Journal:  FEBS Lett       Date:  1998-03-06       Impact factor: 4.124

10.  Neuronal nitric-oxide synthase is regulated by the Hsp90-based chaperone system in vivo.

Authors:  A T Bender; A M Silverstein; D R Demady; K C Kanelakis; S Noguchi; W B Pratt; Y Osawa
Journal:  J Biol Chem       Date:  1999-01-15       Impact factor: 5.157

View more
  4 in total

1.  Exercise training augments neuronal nitric oxide synthase dimerization in the paraventricular nucleus of rats with chronic heart failure.

Authors:  Neeru M Sharma; Xuefei Liu; Tamra L Llewellyn; Kenichi Katsurada; Kaushik P Patel
Journal:  Nitric Oxide       Date:  2019-03-13       Impact factor: 4.427

2.  Dystrophin R16/17-syntrophin PDZ fusion protein restores sarcolemmal nNOSμ.

Authors:  Aman Patel; Junling Zhao; Yongping Yue; Keqing Zhang; Dongsheng Duan; Yi Lai
Journal:  Skelet Muscle       Date:  2018-11-22       Impact factor: 4.912

3.  A Hypothesis for Examining Skeletal Muscle Biopsy-Derived Sarcolemmal nNOSμ as Surrogate for Enteric nNOSα Function.

Authors:  Arun Chaudhury
Journal:  Front Med (Lausanne)       Date:  2015-07-28

4.  Response: "Commentary: A Hypothesis for Examining Skeletal Muscle Biopsy-Derived Sarcolemmal nNOSµ as Surrogate for Enteric nNOSα Function". nNOS(skeletal muscle) may be Evidentiary for Enteric NO-Transmission Despite nNOSµ/α Differences.

Authors:  Arun Chaudhury
Journal:  Front Med (Lausanne)       Date:  2016-02-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.